Michel Dib

2.8k total citations
38 papers, 1.8k citations indexed

About

Michel Dib is a scholar working on Neurology, Physiology and Molecular Biology. According to data from OpenAlex, Michel Dib has authored 38 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Neurology, 8 papers in Physiology and 7 papers in Molecular Biology. Recurrent topics in Michel Dib's work include Amyotrophic Lateral Sclerosis Research (13 papers), Parkinson's Disease Mechanisms and Treatments (7 papers) and Neurotransmitter Receptor Influence on Behavior (5 papers). Michel Dib is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (13 papers), Parkinson's Disease Mechanisms and Treatments (7 papers) and Neurotransmitter Receptor Influence on Behavior (5 papers). Michel Dib collaborates with scholars based in France, Canada and Spain. Michel Dib's co-authors include Vincent Meininger, Alain Favier, Claude Desnuelle, Guy A. Rouleau, Denise A. Figlewicz, Aldis Krizus, Catherine Garrel, Jean-Pierre Julien, Maria‐Grazia Martinoli and Lucette Lacomblez and has published in prestigious journals such as Neurology, Annals of Neurology and Neuroscience.

In The Last Decade

Michel Dib

37 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michel Dib France 18 1.1k 483 460 432 291 38 1.8k
Toshio Mizutani Japan 30 1.1k 1.0× 189 0.4× 720 1.6× 636 1.5× 529 1.8× 115 2.3k
Tomoyoshi Kondo Japan 34 2.2k 2.0× 168 0.3× 954 2.1× 1.4k 3.1× 461 1.6× 132 3.7k
Iddo Magen Israel 24 840 0.8× 166 0.3× 598 1.3× 617 1.4× 215 0.7× 38 2.0k
Andreas Plaitakis United States 26 961 0.9× 160 0.3× 800 1.7× 1.0k 2.3× 204 0.7× 54 2.2k
Silvia Cerri Italy 26 1.1k 1.0× 99 0.2× 714 1.6× 584 1.4× 336 1.2× 61 2.3k
Sylvie Bodard France 23 244 0.2× 97 0.2× 501 1.1× 477 1.1× 168 0.6× 64 1.8k
Albert C. Ludolph Germany 17 780 0.7× 81 0.2× 538 1.2× 634 1.5× 199 0.7× 23 1.4k
Heather McCann Australia 23 1.1k 1.0× 46 0.1× 438 1.0× 520 1.2× 410 1.4× 39 2.0k
Elisabeth Kapaki Greece 25 901 0.8× 63 0.1× 386 0.8× 326 0.8× 333 1.1× 105 2.0k
Jean‐Claude Besnard France 24 483 0.4× 102 0.2× 583 1.3× 740 1.7× 32 0.1× 73 2.5k

Countries citing papers authored by Michel Dib

Since Specialization
Citations

This map shows the geographic impact of Michel Dib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Dib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Dib more than expected).

Fields of papers citing papers by Michel Dib

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Dib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Dib. The network helps show where Michel Dib may publish in the future.

Co-authorship network of co-authors of Michel Dib

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Dib. A scholar is included among the top collaborators of Michel Dib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Dib. Michel Dib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pradat, Pierre‐François & Michel Dib. (2009). Biomarkers in Amyotrophic Lateral Sclerosis. Molecular Diagnosis & Therapy. 13(2). 115–125. 47 indexed citations
2.
Schmidt, Aline, M. Avenel‐Audran, Anne Croué, et al.. (2009). Dermatose neutrophilique aiguë induite par le bortezomib. Annales de Dermatologie et de Vénéréologie. 136(5). 443–446. 9 indexed citations
3.
Landwehrmeyer, G. Bernhard, Bruno Dubois, Justo Garcı́a de Yébenes, et al.. (2007). Riluzole in Huntington's disease: a 3‐year, randomized controlled study. Annals of Neurology. 62(3). 262–272. 139 indexed citations
4.
Ruel, Jérôme, Jing Wang, Rémy Pujol, et al.. (2005). Neuroprotective effect of riluzole in acute noise-induced hearing loss. Neuroreport. 16(10). 1087–1090. 23 indexed citations
5.
Lacomblez, Lucette, et al.. (2005). Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotrophic Lateral Sclerosis. 6(1). 37–44. 78 indexed citations
6.
Kilani, M., Joëlle Micallef, C Soubrouillard, et al.. (2004). A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 5(1). 46–54. 77 indexed citations
7.
Dib, Michel. (2003). Amyotrophic Lateral Sclerosis. Drugs. 63(3). 289–310. 17 indexed citations
8.
9.
Hameg, Ahcène, Franck Baylé, Philippe Nuss, et al.. (2003). Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochemical Pharmacology. 65(3). 435–440. 25 indexed citations
10.
Spreux‐Varoquaux, Odile, Gilbert Bensimon, Lucette Lacomblez, et al.. (2002). Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. Journal of the Neurological Sciences. 193(2). 73–78. 224 indexed citations
11.
Wang, J, Michel Dib, Marc Lenoir, et al.. (2002). Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. Neuroscience. 111(3). 635–648. 67 indexed citations
12.
Álvarez-Guerra, Miriam, Ahcène Hameg, Franck Baylé, Michel Dib, & Ricardo P. Garay. (2002). 5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. European Journal of Pharmacology. 454(2-3). 235–239. 7 indexed citations
13.
Dib, Michel, Catherine Garrel, Alain Favier, Valérie Robin, & Claude Desnuelle. (2002). Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?. Journal of Neurology. 249(4). 367–374. 74 indexed citations
14.
Dib, Michel, et al.. (2002). Efficacy of oral ketoprofen in acute migraine. Neurology. 58(11). 1660–1665. 43 indexed citations
15.
Burg, Mirjam van der, et al.. (2002). A single split-signal FISH probe set allows detection of TAL1translocations as well as SIL-TAL1 fusion genes in a single test. Leukemia. 16(4). 755–761. 9 indexed citations
16.
Desnuelle, Claude, Michel Dib, Catherine Garrel, & Alain Favier. (2001). A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2(1). 9–18. 206 indexed citations
17.
Dib, Michel. (2001). Methodological issues and therapeutic perspectives in vascular dementia: a review. Archives of Gerontology and Geriatrics. 33(1). 71–80. 4 indexed citations
18.
Meininger, Vincent, et al.. (1997). The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. Journal of Neurology. 244(S2). S22–S25. 15 indexed citations
19.
Younes‐Chennoufi, Amena Ben, Michel Dib, P. Bouché, et al.. (1995). Anti-sulfoglucuronyl paragloboside IgM antibodies in amyotrophic lateral sclerosis. Journal of Neuroimmunology. 57(1-2). 111–115. 16 indexed citations
20.
Garofalo, O., Denise A. Figlewicz, P. Nigel Leigh, et al.. (1993). Androgen receptor gene polymorphisms in amyotrophic lateral sclerosis. Neuromuscular Disorders. 3(3). 195–199. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshio Mizutani Breakdown of academic impact, for papers by Tomoyoshi Kondo Breakdown of academic impact, for papers by Iddo Magen Breakdown of academic impact, for papers by Andreas Plaitakis Breakdown of academic impact, for papers by Silvia Cerri Breakdown of academic impact, for papers by Sylvie Bodard Breakdown of academic impact, for papers by Albert C. Ludolph Breakdown of academic impact, for papers by Heather McCann Breakdown of academic impact, for papers by Elisabeth Kapaki Breakdown of academic impact, for papers by Jean‐Claude Besnard
Rankless by CCL
2026